Neutralization Potential as an Assay of Alkalinity of Environmental Solids

2009 ◽  
pp. 160-160-8 ◽  
Author(s):  
WE Grube ◽  
JT Ammons ◽  
JR Freeman
Keyword(s):  
Neutralization Potential

Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral theraphy

2012 ◽  
Vol 50 (1) ◽  
pp. 149-154 ◽  
Author(s):  
Alok Kumar Choudhary ◽  
Raiees Andrabi ◽  
Somi Sankaran Prakash ◽  
Rajesh Kumar ◽  
Shubhasree Dutta Choudhury ◽  
...  
Keyword(s):  
Neutralization Potential ◽  
Indian Patients ◽  
Hiv 1

Micrurus snake species: Venom immunogenicity, antiserum cross-reactivity and neutralization potential

Toxicon ◽  
2016 ◽  
Vol 117 ◽  
pp. 59-68 ◽  
Author(s):  
Gabriela D. Tanaka ◽  
Osvaldo Augusto Sant'Anna ◽  
José Roberto Marcelino ◽  
Ana Cristina Lustoza da Luz ◽  
Marisa Maria Teixeira da Rocha ◽  
...  
Keyword(s):  
Cross Reactivity ◽  
Neutralization Potential ◽  
Snake Species

scholarly journals Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152

2021 ◽  
Author(s):  
Pragya D Yadav ◽  
Gajanan Sapkal ◽  
Raches Ella ◽  
Rima R Sahay ◽  
Dimpal A Nyayanit ◽  
...  
Keyword(s):  
Public Health ◽  
Health Problem ◽  
Public Health Problem ◽  
The Other ◽  
World Health ◽  
Neutralization Titer ◽  
Protective Response ◽  
Neutralization Potential ◽  
Recent Emergence ◽  
Health Organization

Recently, multiple SARS-CoV-2 variants have been detected across the globe.The recent emergence of B.1.617 lineage has created serious public health problem in India. The high transmissibility was observed with this lineage which has led to daily increase in the number of SARS-CoV-2 infections. Apparently, the sub-lineage B.1.617.2 has slowly dominated the other variants including B1617.1, B.617.3 and B.1.1.7. With this, World Health Organization has described B.1.617.2 as variant of concern. Besides this, variant of concern B.1.351 has been also reported from India, known to showreducedefficacyfor many approved vaccines. With the increasing threat of the SARS-CoV-2 variants, it is imperative to assess the efficacy of the currently available vaccines against these variants. Here, we have evaluated the neutralization potential of sera collected from COVID-19 recovered cases (n=20) and vaccinees with two doses of BBV152 (n=17) against B.1.351 and B.1.617.2 compared to the prototype B.1 (D614G) variant.The finding of the study demonstrated a reduction in neutralization titers with sera of COVID-19 recovered cases(3.3-fold and 4.6-fold) and BBV152 vaccinees (3. 0 and 2.7 fold) against B.1.351 and B.1.617.2 respectively. Although, there is reduction in neutralization titer, the whole-virion inactivated SARS-CoV-2 vaccine (BBV152) demonstrates protective response against VOC B.1351 and B.1.617.2.

Sign in / Sign up

Export Citation Format

Share Document